The Department of Surgery at Washington University School of Medicine (WUSM) is one of the nation's leading academic surgery departments, with a strong and uncompromising commitment to training the next generation of academic surgeon-scientists. The Surgical Oncology Basic Science and Translational Research Training Program is a critical component of this overall training goal. The current T32 application will provide surgical trainees from general surgery and other surgical subspecialties the opportunity to develop essential skill sets in basic science, translational, and public health research. The Surgical Oncology Research Training Program has evolved in parallel with a dynamic training environment at WUSM, and currently takes advantage of unique resources in the Department of Surgery, the Siteman Cancer Center, the Division of Biology and Biomedical Sciences, the Institute of Clinical and Translational Sciences, and the Department of Surgery's Division of Public Health Sciences to develop customized and highly structured formal didactic and mentored research experiences for individual surgical trainees. The success of the program is evidenced by the important research accomplishments made by trainees working with program faculty, and the long-term success of trainees in academic medicine. Of note, 5/8 trainees (63%) who have completed the research training program and their clinical training in the last ten years, and 35/60 trainees (58%) who have competed the program since its inception, remain in academic medicine, many with independent funding. Important changes to the Surgical Oncology Research Training Program in this competitive review include additions to the program leadership, development of two distinct research tracks (basic science track, and translational research/public health/clinical effectiveness track), and reduction in the number of training slots to allow for an increase in the tuition budget. These changes will ensure that the Surgical Oncology Research Training Program maintains excellence at the forefront of two different surgical oncology research paradigms, basic science research, and translational/public health/clinical effectiveness research. NCI support will allow WUSM to continue this highly successful research training program, providing the next generation of surgeon- scientists with the research training required to succeed in an increasingly competitive research environment.

Public Health Relevance

Surgeon-scientists are in a unique position to facilitate the clinical translation of basic science research discoveries, with the potential for significant improvements in patient care. The Surgical Oncology Basic Science and Translational Research Training Program will provide surgical trainees from general surgery and other surgical subspecialties the opportunity to develop essential skill sets in basic science, translational, and public health research.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Damico, Mark W
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Washington University
Schools of Medicine
Saint Louis
United States
Zip Code
Tucker, Natalia S; Cyr, Amy E; Ademuyiwa, Foluso O et al. (2016) Axillary Ultrasound Accurately Excludes Clinically Significant Lymph Node Disease in Patients With Early Stage Breast Cancer. Ann Surg 264:1098-1102
Zubovic, Ema; Kodner, Ira J; Brown, Douglas et al. (2016) Ethical challenges of reconsidered informed consent in trauma. Surgery 159:1684-1688
Samson, Pamela; Robinson, Clifford G; Bradley, Jeffrey et al. (2016) The National Surgical Quality Improvement Program risk calculator does not adequately stratify risk for patients with clinical stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 151:697-705.e1
Ohman, Kerri A; Hashim, Yassar M; Vangveravong, Suwanna et al. (2016) Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic. Oncotarget 7:33529-41
Kim, Samuel W; Goedegebuure, Peter; Gillanders, William E (2016) Mammaglobin-A is a target for breast cancer vaccination. Oncoimmunology 5:e1069940
Brauer, David G; Nywening, Timothy M; Jaques, David P et al. (2016) Operative Site Drainage after Hepatectomy: A Propensity Score Matched Analysis Using the American College of Surgeons NSQIP Targeted Hepatectomy Database. J Am Coll Surg 223:774-783.e2
Cyr, Amy E; Tucker, Natalia; Ademuyiwa, Foluso et al. (2016) Successful Completion of the Pilot Phase of a Randomized Controlled Trial Comparing Sentinel Lymph Node Biopsy to No Further Axillary Staging in Patients with Clinical T1-T2 N0 Breast Cancer and Normal Axillary Ultrasound. J Am Coll Surg 223:399-407
Nywening, Timothy M; Wang-Gillam, Andrea; Sanford, Dominic E et al. (2016) Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol 17:651-62
Nwaogu, Iheoma Y; Fayanju, Oluwadamilola M; Jeffe, Donna B et al. (2015) Predictors of pathological complete response to neoadjuvant chemotherapy in stage II and III breast cancer: The impact of chemotherapeutic regimen. Mol Clin Oncol 3:1117-1122
Samson, Pamela; Patel, Aalok; Crabtree, Traves D et al. (2015) Multidisciplinary Treatment for Stage IIIA Non-Small Cell Lung Cancer: Does Institution Type Matter? Ann Thorac Surg 100:1773-9

Showing the most recent 10 out of 124 publications